RT Journal Article
SR Electronic
T1 Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.14.23298578
DO 10.1101/2023.12.14.23298578
A1 Drysdale, Myriam
A1 Hautekiet, Thor
A1 Singh, Moushmi
A1 Hautekiet, Joris
A1 Ludikhuyze, Linda
A1 Patel, Vishal
A1 Gibbons, Daniel C
A1 Roeck, Dorothée De
A1 Colpaert, Kirsten
A1 Lloyd, Emily J
A1 Braeckel, Eva Van
YR 2023
UL http://medrxiv.org/content/early/2023/12/18/2023.12.14.23298578.abstract
AB Background Sotrovimab, a dual-action, engineered human monoclonal antibody, has been demonstrated to significantly reduce the risk of hospitalization and death in high-risk patients with COVID-19. Here, we describe the real-world use of, and outcomes from, sotrovimab treatment in Belgium during the Delta and Omicron waves among patients with COVID-19 at high risk of developing severe disease.Methods This was a multicentric, single-arm observational cohort study of non-hospitalized patients receiving outpatient sotrovimab treatment between 1 November 2021 and 2 August 2022. We performed a retrospective analysis of hospital, pharmacy and administrative data from nine hospitals in Belgium. The primary outcomes were all-cause and COVID-19-related hospitalizations and all-cause deaths during the 29-day acute follow-up period from first administration of sotrovimab.Results A total of 634 patients were included in the analysis (63.4% aged <65 years; 50.3% male). A high proportion (67.7%; n = 429/634) of patients were immunocompromised, with 36.9% (n = 234/634) actively treated for malignancy. During the 29-day acute period, 12.5% (n = 79/634) of sotrovimab-treated patients were hospitalized due to any cause (median duration 4 days; median time to hospitalization 14 days) and 1.1% (n = 7/634) died due to any cause. In total, 0.8% (n = 5/634) of patients were admitted to an intensive care unit (ICU). COVID-19-related hospitalization was experienced by 2.5% (n = 16/634) of patients (median duration 10 days; median time to hospitalization 10.5 days), with 0.5% (n = 3/634) of patients admitted to an ICU. COVID-19-related hospitalization was experienced by 6.3% (n = 3/48) of patients during Delta predominance (04/11/2021–23/12/2021), 6.3% (n = 1/16) of patients during Delta/BA.1 codominance (24/12/2021–01/01/2022), 1.4% (n = 3/218) of patients during BA.1 predominance (02/01/2022–09/02/2022), 2.1% (n = 2/97) of patients during BA.1/BA.2 codominance (10/02/2022–07/03/2022) and 2.7% (n = 7/255) of patients during BA.2/BA.5 codominance (08/03/2022–02/08/2022).Conclusions This observational study demonstrated consistently low rates of COVID-19-related hospitalizations and all-cause deaths in sotrovimab-treated patients during the Omicron subvariant periods in Belgium, despite over two-thirds of the study population being immunocompromised. Comparative effectiveness studies are warranted to confirm sotrovimab effectiveness in highly immunocompromised patients with COVID-19.Competing Interest StatementMS, VP (at time of study), DCG, MD, DDR and EJL are employees of, and/or shareholders in, GSK. JH (at time of study) and LL are employees of IQVIA, which received funding from GSK and Vir Biotechnology, Inc. to conduct the study. TH, KC and EVB are employees of Ghent University Hospital, which received funding from GSK and Vir Biotechnology, Inc. to conduct the study. EVB also declares speaker fees paid to her institution from GSK, Gilead and Pfizer.Funding StatementThis study was funded by GSK and Vir Biotechnology, Inc. (study number 214878).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study complies with all applicable laws regarding subject privacy. No direct subject contact or primary collection of individual human subject data occurred. Study results were in tabular form and were aggregate analyses that omit subject identification; therefore, informed consent was not required. Ethics committee approval was obtained from each of the participating centres (CHU Saint-Pierre - Comite local d'ethique hospitalier [no. 007]; CHU Ambroise Pare - Comite d'ethique hospitalier; AZ Damiaan - Ethisch comite [no. 057]; AZ Sint Lucas Gent - Commissie medische ethiek; Hopital Erasme ULB - Comite d'ethique hospitalo-facultaire; UZ Gent - Commissie voor medische ethiek), with the exception of AZ Maria Middelares, AZ Groeninge and Jan Yperman. For AZ Maria Middelares, formal ethics committee approval is not required for retrospective database studies; however, the study was approved by a data protection board that oversees information security, ethical and financial aspects in the context of secondary reuse of health data. For AZ Groeninge and Jan Yperman, formal ethics approval is not required for retrospective studies; however, a data access committee at each centre (with medical legal and ethics committee representation) approved the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets used and/or analysed during the current study are not available due to data privacy.